Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD)

Dyonne Y. Vos, Bart van de Sluis

ABSTRACT

Background: Metabolic-associated fatty liver disease (MAFLD), also known as non-alcoholic fatty liver disease, has become the leading cause of chronic liver disease worldwide. In addition to hepatic accumulation of triglycerides, dysregulated cholesterol metabolism is an important contributor to the pathogenesis of MAFLD. Maintenance of cholesterol homeostasis is highly dependent on cellular cholesterol uptake and, subsequently, cholesterol transport to other membrane compartments, such as the endoplasmic reticulum (ER).

Scope of review: The endolysosomal network is key for regulating cellular homeostasis and adaptation, and emerging evidence has shown that the endolysosomal network is crucial to maintain metabolic homeostasis. In this review, we will summarize our current understanding of the role of the endolysosomal network in cholesterol homeostasis and its implications in MAFLD pathogenesis.

Major conclusions: Although multiple endolysosomal proteins have been identified in the regulation of cholesterol uptake, intracellular transport, and degradation, their physiological role is incompletely understood. Further research should elucidate their role in controlling metabolic homeostasis and development of fatty liver disease.

Keywords NAFLD; Endosome and lysosome; Cholesterol transport; Endosomal sorting; LDLR; PCSK9

1. INTRODUCTION

Metabolic-associated fatty liver disease (MAFLD, previously known as non-alcoholic fatty liver disease, NAFLD) [1] — the most common cause of chronic liver disease worldwide — refers to a range of liver disorders, but the hallmark of MAFLD is lipid accumulation in the liver (simple steatosis) [2]. Its global prevalence was estimated at 25% in 2018 [2]. The majority of patients have simple steatosis, but approximately 25% of MAFLD patients show signs of liver inflammation (steatohepatitis). Although this inflammatory injury is reversible, it can progress to fibrosis, cirrhosis, and hepatocellular carcinoma [3]. The development of MAFLD is often accompanied by features of metabolic syndrome, such as type 2 diabetes, central obesity, elevated plasma triglycerides (TGs), hypertension, and decreased high-density lipoprotein (HDL) cholesterol [2,4]. Excessive accumulation of hepatic TGs can be the result of disturbed balance in the flux of dietary and adipose tissue-derived free fatty acids (FFAs) to the liver, hepatic de novo lipogenesis (DNL), and mitochondrial β-oxidation of FFAs [3,5]. Studies have also demonstrated that dysregulation of cholesterol metabolism contributes to the pathogenesis of MAFLD [6]. Cholesterol homeostasis is maintained through intracellular cholesterol-sensing machineries and transcription factors that regulate cholesterol synthesis, uptake, and excretion. Disruption of these pathways in MAFLD leads to cholesterol toxicity and lipid accumulation [7].

An essential aspect in the maintenance of cholesterol homeostasis is the intracellular transport of cholesterol. After cholesterol is endocytosed, it is transported through the endolysosomal network, an interconnected network of membranous compartments, which enables the subsequent distribution of cholesterol to other cellular organelles [8,9]. Various studies have demonstrated that impaired functioning of the endolysosomal system results in dysregulated glucose and lipid homeostasis [10—15], which indicates that the endolysosomal network has an important role in metabolic regulation, including cholesterol metabolism. Although most cholesterol transport pathways through subcellular compartments have been well-described [16,17], their mechanisms and regulation remain incompletely understood. This review provides an overview of our current knowledge of the tight regulation of the endolysosomal network and its role in cholesterol homeostasis and in the pathogenesis of MAFLD.

2. THE ENDOLYSOSOMAL NETWORK CONTROLS CELLULAR CHOLESTEROL UPTAKE AND INTRACELLULAR CHOLESTEROL TRANSPORT

The endolysosomal network is crucial for the cell to adapt to intracellular and environmental changes. As it regulates the internalization and sorting of a wide range of integral proteins, such as signaling proteins, it is pivotal for cell function in a variety of physiological processes. This review will summarize the current understanding of the role of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease.
receptors, lysosomal hydrolase receptors, adhesion molecules, and nutrient transporters, it is hence vital for maintaining cellular homeostasis [9]. The cellular uptake of the macromolecule, cholesterol, is highly dependent on receptor-mediated endocytosis (Figure 1). Cholesterol that enters hepatocytes originates mainly from cholesterol-rich low-density lipoprotein (LDL) particles. LDL binds to the LDL receptor (LDLR) at the cell surface, and together they are internalized via clathrin-mediated endocytosis and further transported to early endosomes [18]. Acidification of the endosomal lumen induces dissociation of LDL-cholesterol from LDLR, after which the receptor is either recycled back to the plasma membrane (PM) or directed to the lysosomes for degradation [19] (see also Section 6). LDL-cholesterol is transported to late endosomes and lysosomes (LE/LY), where cholesterol esters (CEs) are hydrolyzed by acid lipases to release free cholesterol. The Niemann-Pick type C2 (NPC2), a small luminal protein, binds to free cholesterol and subsequently delivers it to Niemann-Pick type C1 (NPC1). NPC1 is a large transmembrane protein localized on the limiting membrane of LE/LY [20] (Figure 1). From here, cholesterol is distributed to other cellular compartments [8,9]. The importance of NPC1 and NPC2 in cholesterol transport is illustrated in patients with NPC disease, a severe neurodegenerative disorder caused by loss-of-function mutations in NPC1 or NPC2 [21–23]. Dysfunction of these proteins results in accumulation of cholesterol in LE/LY compartments, leading mainly to neurological symptoms, but also to progressive liver disease characterized by cholestasis, hepatomegaly, and fibrosis or cirrhosis [21—23]. A genome-wide association study identified a single-nucleotide polymorphism (SNP) in NPC1 associated with obesity [24], and NPC1 haploinsufficiency in mice induces hepatosteatosis and features of metabolic syndrome [25]. These findings indicate that NPC1 may play additional roles in metabolic homeostasis other than transporting cholesterol from the LE/LY.

Previously, the membrane protein TMEM97 has been identified as an NPC1-interacting protein and regulator of cellular cholesterol levels [26]. Decreased TMEM97 levels result in enhanced NPC1 protein levels, along with restored cholesterol transport and decreased lipid accumulation in NPC in vitro models [27]. Despite these significant findings, the authors could not substantiate the in vitro results in hepatocytes of a murine NPC model, which indicates that the effect of TMEM97 on NPC1 functioning might be cell type specific [27]. Another study has shown that TMEM97 may also be involved in LDL cholesterol uptake through a direct interaction with LDLR [28]; thus, further research is required to understand the contribution of TMEM97 in NPC disease and hepatic cholesterol uptake.

The importance of the endolysosomal network in cholesterol homeostasis and fatty liver disease is further supported by a study showing that impaired fusion of endolysosomal compartments induces defects

Figure 1: Cholesterol transport through the endolysosomal network. After binding to LDLR, LDL-cholesterol is internalized, and the LDL-LDLR complex is transported to endosomes, where LDL-cholesterol dissociates from LDLR. LDLR can be transported back to the plasma membrane via recycling endosomes (RE). LDL-cholesterol is transported to late endosome/lysosome (LE/LY), where lysosomal acid lipase (LAL) hydrolyzes cholesterol esters to release free cholesterol. TPC2 is important for LE-LY fusion and thus for further cholesterol transport. NPC2 can bind and deliver free cholesterol to NPC1. NPC1 regulates cholesterol transport to other cellular compartments, such as the endoplasmic reticulum (ER) by interacting with Rab7 and the plasma membrane via Rab8b. The ER-located RNF26 recruits and ubiquitinates p62, leading to the binding of specific endosomal-associated adaptor proteins to mediate the positioning of vesicles in the perinuclear area, but its function in cholesterol transport needs to be elucidated. Gramd1b, or Aster-B, is implicated in both LE/LY-to-PM and PM-to-ER cholesterol transport. When cholesterol levels in the ER are low, SREBP1 is translocated to the nucleus, where it induces transcription of genes involved in lipogenesis and cholesterol uptake and synthesis. Cholesterol levels in LE/LY affect lysosomal function and thereby also the autophagic pathway, in which p62 is an important player. Rab24 is thought to reduce autophagy and thereby contribute to MAFLD. The endosomal WASH complex and the retromer subunit VPS35 are also known to affect autophagy, but their physiological role in this context and in MAFLD remain unknown.

Review

9 MOLECULAR METABOLISM 50 (2021) 101146 © 2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

www.molecularmetabolism.com
in LDL cholesterol transport and degradation [29]. Upon activation, the two-pore channel (TPC) 2, a cation channel located mainly in the membrane of LE/LY compartments, releases Ca\(^{2+}\) to regulate endolysosomal fusion processes (Figure 1). Where LE-LY fusion might occur, the ER has a key role in intracellular cholesterol sensing and regulation. Here, cholesterol controls the processing of sterol regulatory-element binding proteins (SREBPs), a family of transcription factors regulating cellular lipid homeostasis (reviewed in [30,31]) (Figure 1). Briefly, by binding to two chaperones, SREBP-cleavage activating protein (SCAP) and insulin-induced gene protein 1 (INSIG1), sterols prevent the translocation of SREBP to the Golgi complex [32,33]. Under sterol-poor conditions, the SCAP-SREBP complex is no longer retained in the ER and is trafficked to the Golgi. Here, SREBP is processed to its mature form, which enters the nucleus to activate the transcription of genes involved in cholesterol synthesis and uptake (mainly by the SREBP-2 isoform) and lipogenesis (mainly by the SREBP-1c isoform) [34].

Studies in patients have indicated that MAFLD is associated with upregulated SREBP expression [35,36], and data from mouse models demonstrate that increased activation of SREBP is a causal factor in the development and progression of fatty liver disease [37–40]. The observation that loss of SREBP-1 upregulates SREBP-2, while SREBP-1 activity depends on functional SREBP-2 signaling [34,41,42], indicates that there is a tight crosstalk and differential regulation of two isoforms. Although several regulators in governing of SREBP signaling have been identified [34], the underlying mechanisms are not fully understood and are currently still being elucidated. Recently, four independent groups have identified C12orf49 as a novel factor that controls SREBP signaling [43–46]. Loregger et al. showed that C12orf49 (dubbed SPRING) controls SREBP signaling by regulating the localization and levels of SCAP [43]. Data from Xiao et al. and Bayraktar et al. indicate that C12orf49 (renamed POST1) mediates SREBP activity through an interaction with site-1 protease (S1P), which cleaves SREBP at the Golgi, followed by a second cleavage of SREBP by site-2 protease (S2P) [44,45,47]. According to Xiao et al., C12orf49 (POST1) promotes formation of the mature form of S1P, subsequently facilitating the translocation of mature S1P from the ER to the Golgi [44]. Thus, the SCAP-SREBP axis to sense intracellular cholesterol content is tightly regulated to maintain lipid homeostasis and prevent hepatic fat accumulation.

4. ENDOlysosomal PROTEINS ARE IMPORTANT REGulators OF CHOLESTEROL TRANSPORT TO THE ER

The exact routes of cholesterol transport from LE/LY to the ER are not clearly defined. Over the past decades, studies have provided evidence that cholesterol released from LE/LY first reaches the PM, prior to distribution of excess cholesterol to the ER [48–51] (Figure 1). However, other studies have shown that cholesterol can also travel directly from LE/LY to the ER [52–55]. It has been estimated that approximately 30% of LDL-derived cholesterol follows this direct pathway, and a study has shown that cyclodextrin, an extracellular acceptor of cholesterol from the PM, blunted only 70% of cholesterol esterification in the ER [52].

Membrane contact sites (MCS), zones where different organelle membranes come into close apposition (10–30 nm) to each other without fusion, have been shown to be sites of non-vesicular cholesterol transfer between organelles [56]. Lipid transfer proteins are required to facilitate this transport by cross-bridging MCS (reviewed in [16]). As such, oxysterol-binding protein-related protein 1L (ORP1L), ORP5, and SIAR-related lipid transfer domain containing 3 (SIARD3) are implicated in direct LE-LY-to-ER cholesterol transport [54,57,58]. Also, the late endosomal protein Rab7 is involved in the formation of LE-LY-ER MCS related to lipid transfer (see section 5). Moreover, a recent study has identified an additional role for NPC1 in the formation of LE-LY-ER MCS by interacting with the ER-resident sterol-binding protein Gramd1b to facilitate cholesterol egress from LE/LY [55].

Another interesting player in LE-LY-to-ER cholesterol transport might be p62/SQSTM1. Although mostly known for its role in autophagy [59] (see also section 7), it was recently shown that p62 participates in a molecular bridge to position related vesicles (e.g., recycling early and late endosomes) in the perinuclear region in an autophagy-independent manner (Figure 2) [60]. Following ubiquitination of p62 by the ER-localized RNF26, endosomal vesicles are recruited to dock at the ER membrane to enable dynamic cargo trafficking [60]. However, it remains unclear whether p62 plays a significant role in cholesterol transport from the endosomal vesicles to the ER and, subsequently, in metabolic diseases, independent of its function in autophagy (section 7).

Although most cholesterol is directly transported to the PM, the mechanisms underlying these transport pathways are not well characterized. One potential pathway is the Rab8a-dependent transport of cholesterol-enriched LE-LY-derived vesicles to the PM (Figure 1). After recruitment of Rab8a to LE/LY by NPC1, cholesterol-enriched vesicles are transported along cortical actin toward the PM, where cholesterol delivery occurs at focal adhesion sites [61]. Interestingly, there is no fusion between the vesicles and PM, suggesting that this pathway might rely on an unidentified MCS [17,61]. In contrast, another potential transport route is associated with LE-PM fusion. Here, the ER-resident protein protrudin interacts with late endosomal Rab7 and phosphatidylinositol 3-phosphate to form ER-LE contacts, and subsequently binds the kinesin-1 motor protein to facilitate plus-end transport of LEs to the PM [62]. To date, it has not yet been determined whether this pathway is linked to cholesterol transfer. Gramd1b, also known as Aster-B, has also recently been implicated in PM-to-ER cholesterol transport [63,64]. This pathway mediates the levels of accessible cholesterol in the PM and thus also the cholesterol levels in the ER, thereby regulating the activity of SREBP signaling [65,66]. The Aster-mediated PM-to-ER cholesterol transport was recently presented as a mechanistic link between increased hepatocyte cholesterol levels in steatosis and progression to fibrotic nonalcoholic steatohepatitis (NASH) through regulation of TAZ [67].

5. RAB GTPASES ARE REQUIRED FOR INTRACELLULAR TRAFFICKING OF LIPIDS

The importance of the endolysosomal system in metabolism and MAFLD has also been illustrated in different mouse studies on the Rab family of small GTPases. In humans, the Rab family consists of more
than 60 members and is known to regulate intracellular membrane traffic between organelles. Specific Rabs are localized on each organelle and associated vesicles, where they act as molecular ‘on/off’ switches to interact with effectors and to regulate the assembly of protein machinery [68].

Rab5, a Rab protein localized to early endosomes (EE), is thought to be required for the biogenesis of the endolysosomal system in vivo and is downregulated in NASH patients [69,70]. Hepatic knockdown of Rab5 was accompanied by severe changes in both glucose and lipid metabolism, including impaired LDL cholesterol uptake, which resulted in increased steroid biosynthesis, hypercholesterolemia, and increased hepatic cholesterol and CE levels [10]. Remarkably, it has been demonstrated that the endosomal Rab5 is also associated with lipid droplets (LDs), lipid-storing organelles that are accumulated in MAFLD. By recruiting early endosomal antigen 1 (EEA1), Rab5 could promote contact between EE and LD [71], but whether these contacts have functional relevance in lipid transfer remains to be elucidated.

In contrast to Rab5, Rab24 is upregulated in livers of obese patients and patients with MAFLD, and this was found to be positively correlated with body fat [72]. Rab24 has been initially identified as a protein localized to LE, ER, and cis-Golgi regions [73,74]. However, in the recent study, knockdown of Rab24 inhibited mitochondrial fission, resulting in enhanced mitochondrial respiration. This was associated with increased autophagic flux [72]. Mechanistically, Rab24 was demonstrated to directly bind the mitochondrial protein FIS1, thereby regulating the assembly of protein machinery required for mitochondrial fission. The upregulation of Rab24 in MAFLD might point to reduced autophagy and decreased mitochondrial respiration, both of which contribute to increased energy storage [72].

The late endosomal protein Rab7, one of the better characterized Rab proteins, is considered a major regulator of late endosomal transport and maturation [75]. In addition, multiple studies have indicated that Rab7 is an important player in the formation of LE/LY-ER MCS to facilitate cholesterol transfer (Figure 1). By interacting with PDZD8 at the ER membrane, Rab7 forms contacts with the ER where lipid transport might occur [76]. Another identified pathway involves AnnexinA6, which inactivates Rab7 by binding the Rab7-GTPase-activating protein TBC1D15 [58]. When AnnexinA6 and TBC1D15 are depleted in NPC1 mutant cells, Rab7 is active, and this is associated with increased SARD3-dependent LE-ER MCS formation, resulting in reduced cholesterol accumulation in LEs. These findings show that in cases of AnnexinA6 deficiency, Rab7 could facilitate cholesterol transfer via LE-ER MCS for storage in LDs [58]. In line with this study, recent findings have demonstrated that cells with inactive Rab7 show impaired intracellular LDL transport and free cholesterol accumulation in LE/LY, whereas Rab7 overexpression in fibroblasts of an NPC patient rescued LE/LY cholesterol accumulation [77]. In addition, active Rab7 was found to interact with NPC1, indicating that Rab7 might be a regulator of NPC1 [77]. Although in vivo evidence is still lacking, these studies illustrate that Rab7 plays a key role in cholesterol egress from the endolysosomal system. In addition to its localization to endolysosomal compartments, Rab7 is also found on autophagosomes. Here, Rab7 is involved in multiple autophagic processes (reviewed in [75]), including the regulation of lipid degradation (‘lipophagy’), by driving fusion between LE/LY and autophagic LDs [78].
6. THE ENDOosomal SORTING MACHINERY IS ESSENTIAL FOR HEPATIC CHOLESTEROL UPTAKE

Cholesterol that is taken up by the liver is derived mainly from plasma LDL cholesterol, which is internalized through LDLR [79], a mechanism that was described for the first time in the 1980s by Goldstein and Brown. Mutations in LDLR cause familial hypercholesterolemia (FH) [80], an autosomal dominant disorder characterized by very high plasma LDL cholesterol levels and increased risk of premature atherosclerotic cardiovascular disease [81]. Although mutations in LDLR are the most prevalent causal mutations among FH patients, mutations in genes regulating LDLR endocytosis, trafficking, and degradation are also associated with FH (reviewed in [82,83]). Identification of these genes has been crucial for the current molecular understanding of the intracellular LDLR trafficking pathway and the hepatic cholesterol uptake machinery [82].

After internalization of the LDL-LDLR complex and arrival at the endosomes, LDLR can be sorted toward the lysosomes for degradation or be directed back to the PM for reuse (Figure 2). Degradation of the receptor is coordinated by two distinct pathways (Figure 2). The inducible degrader of the LDL receptor (IDOL) ubiquitinates LDLR intracellularly, thereby tagging it for degradation, while proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates LDLR proteolysis by binding to the receptor either intracellularly or extracellularly [84–87]. Intracellularly, PCSK9 and LDLR can interact within the secretory pathway, and this leads to direct trafficking of the receptor from the Golgi network to the LE/LY for degradation [87]. Extracellular binding of circulating PCSK9 to LDLR at the PM is followed by endocytosis of the PCSK9-LDLR complex, a process dependent on the adaptor protein ARH [86]. In the endosomes, PCSK9 prevents the acid-dependent conformational change of LDLR necessary for its recycling to the PM, thereby stimulating degradation of the receptor in the LE/LY [88,89]. In addition to the inhibition of the extracellular binding of PCSK9 to LDLR through antibody-based therapies, blocking both the intracellular and the extracellular PCSK9-mediated LDLR degradation pathway by RNA-targeted therapy successfully lowers plasma LDL cholesterol and the risk of atherosclerotic cardiovascular disease [90,91].

Although the LDLR degradation pathways are well described, the mechanisms coordinating LDLR recycling were not understood until recently, when studies demonstrated that two protein complexes of the endosomal sorting machinery, CCC (CCOMMD/CCDC22/CCDC93) and WASH (Wiskott-Aldrich syndrome protein and SCAR homolog) [82–94], facilitate the recycling of LDLR back to the PM (Figure 2) [12,13]. The CCC complex consists of three core components, coiled-coil domain-containing (CCDC) CCDC22, CCDC93, and C16orf62 (recently renamed to VPS35L) and members of the Copper Metabolism MURR1 Domain-containing (COMMD) protein family [82]. Previous studies have shown that the CCC complex interacts with the WASH complex to maintain copper homeostasis by facilitating the endosomal trafficking of the copper-transporting proteins ATP7B and ATP7A [92,95–100]. The WASH complex is composed of five subunits (WASHC1-C5) and activates the actin-related protein 2/3 (Arp2/3) complex to induce actin polymerization at endosomal sorting domains, which is required for endosomal receptor trafficking (Figure 2) [93,94].

Recently, the CCC complex has been shown to regulate the level and activity of WASH on the endosomal compartment to control endosomal protein recycling [101]. In mice and dogs, lack of one of the components of the CCC complex destabilizes the entire CCC core complex, resulting in reduced LDLR levels at the PM, enhanced lysosomal degradation of LDLR, impaired LDL cholesterol uptake, and ultimately increased plasma LDL cholesterol [13,102]. Furthermore, in ApoE3-Leiden mice, a mouse model with a human-like lipoprotein profile, perturbation of the CCC complex exacerbates dyslipidemia and atherosclerosis [13].

In humans, hypomorphic mutations in CCDC22 cause the severe developmental disorder X-linked intellectual disability (XLID) [103,104], and a homozygous splice site mutation in WASHC5 causes Ritscher-Schinzel Syndrome 1 [105], both severe developmental disorders. XLID and Ritscher-Schinzel Syndrome 1 patients also suffer from hypercholesterolemia, illustrating that, across species, the endosomal recycling machinery is conserved to maintain cholesterol homeostasis [102]. Furthermore, a recent study revealed that a common genetic variant in CCDC93 in humans is associated with reduced plasma LDL cholesterol levels, and correlated with lower risk of myocardial infarction and cardiovascular mortality [106]. The variant is associated with enhanced stability of the CCDC93 protein and probable improved functioning of the CCC complex, likely leading to better LDLR recycling and reduced plasma LDL cholesterol levels [106].

The WASH complex acts in concert with the CCC complex, and hepatic loss of the WASH components also results in increased plasma LDL cholesterol due to impaired endosomal trafficking of LDLR [14,102]. In addition to impaired recycling of the LDLR, hepatic WASH depletion also impairs endosomal recycling of LDLR-related protein 1 (LRP1) and scavenger receptor class B type I (SR-BI) [14]. LRP1 cooperates with LDLR in the uptake of remnant lipoproteins [107], while SR-BI mediates the uptake of CE from high-density lipoprotein particles [108]. Furthermore, it has been shown that the PCSK9-mediated LDLR degradation pathway does not rely on the endosomal LDLR trafficking itinerary facilitated by the WASH complex, whereas IDOL-dependent LDLR degradation does [14,109] (Figure 2). Taken together, the CCC/WASH axis seems to be essential for the endosomal trafficking of the lipoprotein receptors LDLR, LRP1, and SR-BI, and hence for hepatic uptake of cholesterol carried by different lipoproteins. Mechanistically, it is well established that WASH is recruited to the endosomes by a trimeric protein complex called retromer, which is composed of VPS35, VPS26, and VPS29 [110,111] (Figure 2). Retromer is known to coordinate endosomal trafficking of a wide variety of cargo molecules, including Glut1, β2 adrenergic receptor, cation-dependent mannose-6-phosphate receptor (Cl-M6PR), and sortilin (see section 7) [112–115]. However, a distinct retromer-independent trafficking pathway has recently been revealed by the identification of retriever, a retromer-like protein complex consisting of VPS35L (previously C16orf62), VPS26C (previously DSCR3) and VPS29 [116]. In vitro studies have shown that VPS35L does participate in the receptor as well as in the CCC complex [13,92,116] (Figure 2). Retriever localizes to the endosomes by binding to the CCC complex, and associates with both CCC and WASH to promote cargo retrieval and recycling [116]. Retriever may facilitate cargo recycling by coupling to sorting nexin SNX17 (Figure 2), an adaptor protein known to mediate sorting of proteins with Npx1/NoxY-sorting motifs in their intracellular cytosolic domains, such as LRP1 and LDLR [116–119]. Although in vitro studies have implicated that retriever facilitates the recycling of members of the LDLR family and retromer SR-BI [113,116], it remains unclear whether these complexes are indeed required for the endosomal transport of these receptors in vivo. Likewise, it has not yet been determined whether a functional interaction takes place between the CCC/WASH axis and the adaptor protein phosphotyrosine interacting domain containing 1 (Pit1). Pit1 was recently shown to mediate hepatic uptake of lipoproteins by regulating the localization of LRP1 [15]. In summary, these findings indicate that the intracellular trafficking of lipoprotein receptors for
hepatic cholesterol uptake is tightly regulated by several proteins, but how these are interconnected to maintain cholesterol homeostasis remains to be resolved.

In addition, it is important to note that altered cholesterol homeostasis changes membrane fluidity and domain formation, which can alter receptor trafficking and their downstream signaling pathways [8,120,121]. It is evident that changes in membrane cholesterol composition can directly modify the motility and functional properties of endolysosomal compartments, thereby affecting intracellular cargo trafficking and transport [122–124]. In addition, the positioning of LE/LY and formation of LE/LY-ER contacts is highly dependent on cholesterol levels [125]. This has also been observed in models of endolysosomal cholesterol accumulation, such as in NPC disease or other lysosomal storage diseases, which results in clustering of LE/LY and defects in vesicle trafficking [126–128]. Taken together, these data suggest that there is a bidirectional connection between cholesterol homeostasis and intracellular cargo trafficking, which indicate that intracellular cholesterol accumulation observed in metabolic diseases, such as in MALFD, might influence the functioning of the endolysosomal system.

7. ENDOSOMAL SORTING PROTEINS AFFECT LIPID METABOLISM BEYOND REGULATING CHOLESTEROL UPTAKE

Mice with a hepatic deficiency of the CCC component COMMD1 are more prone to develop diet-induced hepatic steatosis [129]. The underlying mechanism is unclear, but depletion of the CCC-associated WASH complex results in decreased expression of genes regulated by the transcription factor liver X receptor (LXR) [14]. LXR regulates the expression of genes involved in fatty acid synthesis, as well as cholesterol efflux and excretion, and increased LXR activity is associated with hepatic steatosis [14,130]. Despite the reduced LXR activity, hepatic WASH-deficient chow-fed mice did not show differences in hepatic cholesterol and triglyceride levels [14]. It is furthermore interesting to mention that the WASH component WASHC2 (FAM21) is also localized to ER tubules [131]. Recent studies have shown that MQR between ER and endosomes are essential for the position and timing of WASH-associated endosomal fission events [33,131], yet there is no direct evidence for the role of WASH in the formation of endosome-ER MQR nor in cholesterol transport between these organelles.

It is known that MAFLD is associated with lysosomal dysfunction and impaired autophagy. MAFL patients show reduced expression of lysosomal acid hydrolases and lysosomal acid lipase (LAL), which hydrolyzes CE and TG [132–134]. Deficiency of LAL results in lysosomal cholesterol accumulation and induces dyslipidemia and steatosis [135]. Macrophagy, the best studied form of autophagy (hereafter referred to as autophagy), is a lysosome-mediated degradation process for removal of intracellular material, such as organelles and protein aggregates, to provide energy during nutrient deprivation. Intracellular materials are sequestered by autophagosomes, which then fuse with lysosomes to form autolysosomes, where contents are degraded by lysosomal acid hydrolases (Figure 2) [136]. In 2008, the first link between autophagy and lipid metabolism was demonstrated by Singh et al., who reported that autophagy regulates breakdown of triglycerides (lipophagy) and may thus have anti-atherogenic properties [137]. Although some findings are still contradictory, possibly due to contextual differences between studies, the current consensus is that autophagy is reduced in MAFLD (reviewed by [138,139]). As autophagy is closely related to lysosomal function, it is therefore not surprising that conditions involving lysosomal cholesterol accumulation, such as NPC disease, have been associated with autophagic dysfunction. Lysosomal cholesterol accumulation increases the induction of autophagy, resulting in impaired autophagosome clearance and accumulation of autophagosome vacuoles in NPC cells [140–142]. In addition, free cholesterol loading in HepG2 cells results in autolysosomal accumulation and impaired clearance of autolysosome cargo [143]. This suggests that accumulation or mistrafﬁcking of lipids modulates autophagic processes. On the other hand, inhibition of autophagy could decrease lysosomal cholesterol accumulation in NPC cells [142], which shows that the interaction between lipids and the autophagic pathway works both ways.

Interestingly, WASH deﬁciency in MEFs and mouse hepatocytes alters the architecture of the endolysosomal network [14,94,144], with smaller and more tubulated lysosomes [14]. These endolysosomal abnormalities are accompanied by increased autophagic ﬂux in MEFs [145]. In addition to WASH, retromer has also been linked to lysosomal dysfunction and autophagy through its regulation of CI-M6PR and ATG9 trafficking [114,115,146]. CI-M6PR is one of the sorting receptors responsible for delivering acid hydrolases to LY [147]. These hydrolases are required for proper lysosomal function, and impaired delivery results in reduced lysosomal proteolytic capacity [148]. Mislocalization of CI-M6PR by aberrant retromer function in MEFs deﬁcient in the small GTPase Arf6 was accompanied by free cholesterol accumulation in LE/LY [149]. This accumulation was associated with mislocalization of NPC2, likely due to mistrafﬁcking of CI-M6PR [149], a known transporter of NPC2 [150]. In addition, the Parkinson’s disease-related VPS35 mutation is associated with impaired autophagy, likely by decreased recruitment of the WASH complex to the endosomes, as loss of WASH in HeLa cells also results in a defect in autophagy [151]. Although these data are contrary to the results observed in WASH1-deficient MEFs [145], these findings clearly indicate a role for WASH and retromer in both lysosomal function and autophagy (Figure 1). However, hepatic WASH1 deﬁciency in mice on a regular diet does not affect hepatic cholesterol or triglyceride content; thus whether hepatic WASH plays a role in autophagy, and subsequently in hepatic lipid accumulation, requires further investigation. Additional studies are also required to elucidate the contribution of retromer to lysosomal function and autophagy and, hence, to MAFLD. Another known cargo of retromer is sortilin [112]. Sortilin, member of the vacuolar protein sorting 10 protein (Vps10p) domain family, is a lysosomal sorting receptor that delivers ligands mainly from the Golgi network to endolysosomal compartments and is subsequently transported back to the Golgi by retromer [112]. Sortilin is a known regulator of lipoprotein metabolism, as it is shown to regulate VLDL production and to be involved in LDL uptake, independent of LDLR (reviewed in [152]). However, some findings regarding the role of sortilin in lipid metabolism are contradictory, indicating that its action is rather complex [152,153]. Interestingly, several reports have demonstrated that deficiency of sortilin in mice with diet-induced obesity attenuates hepatic steatosis [154,155]. Mechanistically, this effect has been linked with reduced activity of acid sphingomyelinase (aSMase) [155]. In addition, sortilin-deﬁcient mice fed a high-fat diet showed decreased free cholesterol accumulation due to reduced lysosomal targeting and degradation of cardiolipinase 1, an enzyme that catalyzes the breakdown of cholesterol esters in the liver [156]. Furthermore, loss of the hepatic (pro)receptor reduces sortilin-dependent LDL uptake [157]. Altogether, these data indicate that the retromer-cargo sortilin may be an important factor in MALFD and hepatic LDL cholesterol uptake.
REFERENCES

None declared.

CONFLICT OF INTEREST

None declared.

ACKNOWLEDGMENTS

This work was supported by grants from the European Union (MSCA-ITN-2020, 953489; Acronym EndoConnect coordinated by B.v.d.S.) and the Netherlands Cardiovascular Research Initiative: ‘the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development and the Royal Netherlands Academy of Sciences’ (CVON2017-2020; Acronym Genius2).

8. CONCLUSIONS

In vitro studies have established that the endolysosomal network is essential for controlling cell homeostasis [9], but emerging evidence now shows that it is also crucial in maintaining metabolic homeostasis at the organismal level. Dysfunction of endolysosomal proteins can directly impair multiple steps of the endolysosomal pathways, thereby deregulating cellular and organismal homeostasis and contributing to disease development [156]. Recent studies have identified multiple endolysosomal proteins that regulate uptake, sorting, intracellular transport, and degradation of proteins and lipids. Some of these proteins have already been implicated in the pathogenesis of MAFLD, but the physiological role of most proteins is still not well understood. Further research is needed to enhance our understanding of their contribution to MAFLD and whether their functioning is affected by metabolic challenges [159].

REFERENCES

[1] Eslam, M., Sanyal, A.J., George, J., 2020. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158(7):1999–2014. https://doi.org/10.1053/j.gastro.2019.11.312.
[2] Chalasani, N., Younossi, Z., Lavine, J.E., Charlton, M., Cusi, K., Rinella, M., et al., 2018. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67(1):328–357. https://doi.org/10.1002/hep.29367.
[3] Haas, J.T., Francque, S., Staels, B., 2016. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annual Review of Physiology 78:181–205. https://doi.org/10.1146/annurev-physiol-021115-105331.
[4] Cotter, T.G., Rinella, M., 2020. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology 158(7):1851–1864. https://doi.org/10.1053/j.gastro.2020.01.052.
[5] Browning, J.D., Horton, J.D., 2004. Molecular mediators of hepatic steatosis and liver injury. Journal of Clinical Investigation 114(2). https://doi.org/10.1172/JCI200422422. The.
[6] Min, H., Kapoor, A., Fuchs, M., Mirshahi, F., Zhou, H., Maher, J., et al., 2012. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metabolism 15(5):665–674. https://doi.org/10.1016/j.cmet.2012.04.004.
[7] Muss0, G., Gambino, R., Cassader, M., 2013. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Progress in Lipid Research 52(1):175–191. https://doi.org/10.1016/j.plipres.2012.11.002.
[8] Ikonen, E., 2008. Cellular cholesterol trafficking and compartmentalization. Nature Reviews Molecular Cell Biology 9:125–138. https://doi.org/10.1038/nrm2336.

[9] Budick-Harmelin, N., Miaczynska, M., 2018. Integration of the endocytic system into the network of cellular functions. In: Lamaze, C., Prior, I. (Eds.), Endocytosis and signaling. Cham: Springer International Publishing, p. 39–63.
[10] Zeigerer, A., Bogorad, R.L., Sharma, K., Gilleron, J., Seifert, S., Sales, S., et al., 2015. Regulation of liver metabolism by the endosomal GTPase Rab5. Cell Reports 11:804–892. https://doi.org/10.1016/j.celrep.2015.04.018.
[11] Gilleron, J., Gerdes, J.M., Zeigerer, A., 2019. Metabolic regulation through the endosomal system. Traffic 20:552–570.
[12] Bartuzi, P., Billadeau, D.D., Favier, R., Rong, S., Dekker, D., Fedoseienko, A., et al., 2016. CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL. Nature Communications 7:1–11. https://doi.org/10.1038/ncomms10961.
[13] Fedoseienko, A., Wijers, M., Wolters, J.C., Dekker, D., Smit, M., Huijkmans, N., et al., 2018. COMMD family regulates plasma LDL levels and attenuates atherosclerosis through stabilizing the CCC complex in endosomal LDLR trafficking. Circulation Research 122(12):1648–1660. https://doi.org/10.1161/CIRCRESAHA.117.312004.
[14] Wijers, M., Zanoni, P., Liv, D.Y., Jäckstein, M.Y., Smit, M., et al., 2019. The hepatic WASH complex is required for efficient plasma LDL and HDL cholesterol clearance. JCI Insight 4(11):e126462. https://doi.org/10.1172/jci.insight.126462.
[15] Fischer, A.W., Albers, K., Krott, L.M., Hoffzimmer, B., Heine, M., Schmale, H., et al., 2018. The adaptor protein PID1 regulates receptor-dependent endosomal sorting of postprandial triglyceride-rich lipoproteins. Mol Metab 16:88–99. https://doi.org/10.1016/j.molmet.2018.07.010.
[16] Luo, J., Jiang, L., Yang, H., Song, B., 2019. Intracellular cholesterol transport by sterol transfer proteins at membrane contact sites. Trends in Biochemical Sciences 44(3):273–292. https://doi.org/10.1016/j.tibs.2018.10.001.
[17] Martello, A., Platt, F.M., Eden, E.R., 2020. Staying in touch with the endocytic network: the importance of contacts for cholesterol transport. Traffic 21(5):354–363. https://doi.org/10.1111/tra.12726.
[18] Chen, W.J., Goldstein, J.L., Brown, M.S., 1990. NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor. Journal of Biological Chemistry 265(6):3116–3123.
[19] Rudenko, G., Henry, L., Henderson, K., Ichtenchenko, K., Brown, M.S., Goldstein, J.L., et al., 2002. Structure of the LDL receptor extracellular domain at endosomal pH. Science 298:2353–2358.
[20] Infante, R.E., Wang, M.L., Radhakrishnan, A., Kwon, H.J., Brown, M.S., Goldstein, J.L., 2008. NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. Proceedings of the National Academy of Sciences 105(40):15287–15292.
[21] Kelly, D.A., Portmann, B., Mowat, A.P., Sherlock, S., Lake, B.D., 1993. Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease. The Journal of Pediatrics 123(2):242–247.
[22] Vanier, M.T., 2010. Niemann-Pick disease type C. Orphanet Journal of Rare Diseases 5:1–18.
[23] Patterson, M.C., Hendriksz, C.J., Wellerfang, M., SedeI, F., Vanier, M.T., Wijburg, F., 2012. Recommendations for the diagnosis and management of Niemann—pick disease type C; an update. Molecular Genetics and Metabolism 106(3):330–344. https://doi.org/10.1002/mgen.2012.03.012.
[24] Moyre, D., Delplanque, J., Chavre, J.-C., Lecoour, C., LobbenS, S., GallinA, S., et al., 2009. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nature Genetics 41(2):157–159. https://doi.org/10.1038/ng.301.
[25] Jelinek, D., Millward, Y., Bird, A., Trouard, T.P., Heidenreich, R.A., Garver, W.S., 2011. NpC1 haploinsufficiency promotes weight gain and metabolic features associated with insulin resistance. Human Molecular Genetics 20(2):312–321. https://doi.org/10.1093/hmg/ddq466.
Review

[26] Bartz, F., Kern, L., Erz, D., Zhu, M., Gilbert, D., Meinhof, T., et al., 2009. Identification of cholesterol-regulating genes by targeted RNA screening. Cell Metabolism 10:63–75. https://doi.org/10.1016/j.cmet.2009.05.009.

[27] Ebrahimi-Fakhari, D., Wahltaster, L., Bartz, F., Werenbeck-ueding, J., Praggastis, M., Zhang, J., et al., 2016. Reduction of TMEM97 increases NPC1 protein levels and restores cholesterol trafficking in Niemann-pick type C1 disease cells. Human Molecular Genetics 25(16):3586–3599. https://doi.org/10.1093/hmg/ddw204.

[28] Riad, A., Zeng, C., Weng, C.-C., Winters, H., Xu, K., Makvandi, M., et al., 2018. Sigma-2 receptor/TMEM97 and PGRMC-1 increase the rate of internalization of LDL by LDL receptor through the formation of a ternary complex. Scientific Reports 8:16845. https://doi.org/10.1038/s41598-018-35430-3.

[29] Grimm, C., Holdt, L.M., Chen, C.-C., Hassan, S., Müller, C., Jörs, S., et al., 2017. Expression of SREBP-1c requires SREBP-2-mediated generation of a sterol ligand for LXR in livers of mice. Elife 6:e25015. https://doi.org/10.7554/elife.25015.

[30] Shimano, H., Brown, M.S., Horton, J.D., 1997. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. Journal of Clinical Investigation 100(8):2115–2124.

[31] Aregger, M., Lawson, K.A., Billmann, M., Costanzo, M., Tong, A.H.Y., Chan, K., et al., 2020. Systematic mapping of genetic interactions for de novo fatty acid synthesis identifies C12orf49 as a regulator of lipid metabolism. Nat Metab 2(6):487–498. https://doi.org/10.1038/s42255-020-0060-9.

[32] Brown, M.S., Radhakrishnan, A., Goldstein, J.L., 2018. Retrospective on molecular Medicine 21:507. https://doi.org/10.1093/hmg/ddw204.

[33] Shimano, H., Sato, R., 2017. SREBP-regulated lipid metabolism: convergent physiology — divergent pathophysiology. Nature Reviews Endocrinology 13: 710–730. https://doi.org/10.1038/nrendo.2017.91.

[34] Brown, M.S., Radhakrishnan, A., Goldstein, J.L., 2018. Retrospective on cholesterol Homeostasis: the central role of scap. Annual Review of Biochemistry.

[35] Sun, L., Li, L., Goldstein, J.L., Brown, M.S., 2005. Insg required for sterol-mediated inhibition of scap/SREBP binding to COPII proteins in vitro. Journal of Biological Chemistry 280(28):26483–26490. https://doi.org/10.1074/jbc.M504041200.

[36] Kohjima, M., Higuchi, N., Kato, M., Kotoh, K., Yoshimoto, T., Fujino, T., et al., 2008. SREBP-1c, regulated by the insulin and AMPK signaling pathways , plays a role in nonalcoholic fatty liver disease. International Journal of Molecular Medicine 21:507–511.

[37] Shimano, H., Goldstein, J.L., Brown, M.S., 2005. Insg required for sterol-mediated inhibition of scap/SREBP binding to COPII proteins in vitro. Journal of Biological Chemistry 280(28):26483–26490. https://doi.org/10.1074/jbc.M504041200.

[38] Brown, M.S., Radhakrishnan, A., Goldstein, J.L., 2018. Retrospective on cholesterol Homeostasis: the central role of scap. Annual Review of Biochemistry.

[39] Neufeld, E.B., Cooney, A.M., Pitha, J., Dawidowicz, E.A., Dwyer, N.K., Pentchev, P.G., et al., 1996. Intracellular traficking of LDL cholesterol from lysosome to plasma membrane to ER is governed by phosphatidylserine. Proceedings of the National Academy of Sciences 93(September):11235–11240.

[40] Neufeld, E.B., Cooney, A.M., Pitha, J., Dawidowicz, E.A., Dwyer, N.K., Pentchev, P.G., et al., 1996. Intracellular traficking of LDL cholesterol from lysosome to plasma membrane to ER is governed by phosphatidylserine. Proceedings of the National Academy of Sciences 93(September):11235–11240.
[57] Du, X., Kumar, J., Ferguson, C., Schulz, T.A., Ong, Y.S., Hong, W., et al., 2011. A role for oyster–binding protein–related protein 5 in endosomal cholesterol trafficking. Journal of Cell Biology 192(1):121–135. https://doi.org/10.1083/jcb.2010044142

[58] Meneses-Salas, E., García-Melero, A., Kanerva, K., Blanco-Muñoz, P., Morales-Paytov, F., Bonjoch, J., et al., 2020. Annexin A6 modulates TBC1D15/Rab7/SARD3 axis to control endosomal cholesterol export in NPC1 cells. Cellular and Molecular Life Sciences 77:2839–2857.

[59] Lamark, T., Svenning, S., Johansen, T., 2017. Regulation of selective autophagy: the p62/SQSTM1 paradigm. Essays in Biochemistry 61(6):609–624. https://doi.org/10.1042/EBC20170035

[60] Jongsma, M.L.M., Berlin, I., Wijdeven, R.H.M., Janssen, L., Janssen, G.M.C., Garstka, M.A., et al., 2016. An ER-associated pathway defines endosomal architecture for controlled cargo transport. Cell 166(1):152–166. https://doi.org/10.1016/j.cell.2016.05.078

[61] Kanerva, K., Uronen, R.-L., Blom, T., Li, S., Lappalainen, P., Lamark, T., Svenning, S., Johansen, T., 2017. Regulation of selective autophagy: the p62/SQSTM1 paradigm. Essays in Biochemistry 61(6):609–624. https://doi.org/10.1042/EBC20170035

[62] Liu, P., Bartz, R., Zehmer, J.K., Ying, Y., Zhu, M., Serrero, G., et al., 2012. Rab5 is necessary for the biogenesis of the endolysosomal system in vivo. Nature 485(7399):465–470. https://doi.org/10.1038/nature11133

[63] Sahin, N., Brolač, J., 2016. Genomics of human fatty liver disease reveal mechanistically linked lipid droplet – associated gene regulations in bland steatosis and nonalcoholic steatohepatitis. Translational Research 177:41–69. https://doi.org/10.1016/j.trsl.2016.06.003

[64] Liu, P., Bartz, R., Zehmer, J.K., Ying, Y., Zhu, M., Serrero, G., et al., 2007. Rab-regulated interaction of early endosomes with lipid droplets. Biochimica et Biophysica Acta 1773:784–793. https://doi.org/10.1016/j.bbadis.2007.02.004

[65] Seitz, S., Kwon, Y., Hartleben, G., Jürg, J., Sekar, R., Krahmer, N., et al., 2019. Hepatic Rab24 controls blood glucose homeostasis via improving mitochondrial plasticity. Nat Metab 1(10):1009–1026. https://doi.org/10.1038/s42255-019-0124-x

[66] Amaya, C., Milletello, R.D., Caligaris, S.D., Colombo, M.I., 2016. Rab24 interacts with the Rab7/Rab interacting lysosomal protein complex to regulate endosomal degradation. Traffic 17(11):1181–1196. https://doi.org/10.1111/tra.12431

[67] Oikonen, V.M., Dupree, P., Killisch, I., Lüdtke, A., Zerjal, M., Simons, K., 1993. Molecular cloning and subcellular localization of three GTP-binding proteins of the Rab subfamily. Journal of Cell Science 106:1249–1261.

[68] Guerra, F., Bucci, C., 2016. Multiple roles of the small GTPase Rab7. Cells 5(3):1–28. https://doi.org/10.3390/cells5030034

[69] Guillin-Samander, A., Biau, X., Camilli, P., De., 2019. PDZD8 mediates a Rab7-dependent interaction of the ER with late endosomes and lysosomes. Proceedings of the National Academy of Sciences 116(45):22619–22623.

[70] Boonen, Van Den, D.J.H., Slenkiewicz, A., Berlin, I., Jongsma, M.L.M., Elizalde, D.M.V., et al., 2020. A trimeric Rab6 GEF controls NPC1-dependent lysosomal cholesterol export. Nature Communications 11:5559. https://doi.org/10.1038/s41467-020-19032-0

[71] Schroeder, B., Schulze, R.J., Weller, S.G., Sletten, A.C., Casey, C.A., McNiven, M.A., 2016. The small GTPase Rab7 as a central regulator of hepatocellular lipophagy. Hepatology 61(6):1896–1907. https://doi.org/10.1002/hep.27667

[72] Brown, M.S., Goldstein, J.L., 1986. A receptor-mediated pathway for cholesterol homeostasis. Science 232(4764):34–47.

[73] Goldstein, J.L., Brown, M.S., 1989. Familial hypercholesterolaemia. In: Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D. (Eds.), The metabolic basis of inherited disease. New York: McGraw-Hill. p. 1215–50.

[74] Usifo, E., Leigh, S.E.A., Whittall, R.A., Lench, N., Taylor, A., Yeats, C., et al., 2012. Low-density lipoprotein receptor gene familial hypercholesterolemia variant Database: update and pathological assessment. Annals of Human Genetics 76:387–401. https://doi.org/10.1111/j.1469-1809.2012.00724.x

[75] Wijers, M., Kuivenhoven, J.A., Van De Sluis, B., 2015. The life cycle of the low-density lipoprotein receptor: insights from cellular and in-vivo studies. Current Opinion in Lipidology 26(2):82–87. https://doi.org/10.1097/MOL.0000000000000157

[76] Berberich, A.J., Hegele, R.A., 2019. The complex molecular genetics of familial hypercholesterolaemia. Nature Reviews Cardiology 16:9–20. https://doi.org/10.1038/s41569-018-0052-6

[77] Zeilner, N., Hong, C., Boyadjian, R., Tontonoz, P., 2009. LXR regulates cholesterol uptake through idol-dependent ubiquitination of the LDL receptor. Science 325(5936):100–104. https://doi.org/10.1126/science.1168974

[78] Scotti, E., Calamai, M., Goulbourne, C.N., Zhang, L., Hong, C., Choi, J., et al., 2013. IDOL stimulates clathrin-independent endocytosis and multisvesicular body-mediated lysosomal degradation of the low-density lipoprotein receptor. Molecular and Cellular Biology 33(8):1503–1514. https://doi.org/10.1128/MCB.01716-12

[79] Lagace, T.A., Curtis, D.E., Garuti, R., McNutt, M.C., Park, S.W., Prather, H.B., et al., 2006. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. Journal of Clinical Investigation 116(11):2995–3004. https://doi.org/10.1172/JCI29383

[80] Poirier, S., Mayer, G., Poupon, V., McPherson, P.S., Desjardins, R., Ly, K., et al., 2009. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation. Journal of Biological Chemistry 284(42):28856–28864. https://doi.org/10.1074/jbc. M109.037085

[81] Zhang, D.-W., Lagace, T.A., Garuti, R., Zhao, Z., McDonald, M., Horton, J.D., et al., 2007. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. Journal of Biological Chemistry 282(25):18602–18612. https://doi.org/10.1074/jbc. M702072200.
Review

[89] Zhang, D.-W., Garuti, R., Tang, W.-J., Cohen, J.C., Hobbs, H.H., 2008. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proceedings of the National Academy of Sciences 105(39):13045–13050.

[90] Ference, B.A., Ginsberg, H.N., Graham, I., Ray, K.K., Packard, C.J., Bruckert, E., et al., 2017. Low-density lipoproteins cause atherosclerotic cardiovascular disease . 1 . Evidence from genetic , epidemiologic , and clinical studies . A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 38:2459–2472. https://doi.org/10.1093/eurheartj/ehx144.

[91] Sinning, D., Landmesser, U., 2020. Low-density lipoprotein-cholesterol lowering strategies for prevention of atherosclerotic cardiovascular disease: focus on siRNA treatment targeting PCSK9 (inclisiran). Current Cardiology Reports 22:176.

[92] Phillips-Krawczak, C.A., Singla, A., Starokadomsky, P., Deng, Z., Osborne, D.G., Li, H., et al., 2015. COMMD1 is linked to the WASH complex and regulates endosomal trafficking of the copper transporter ATP7A. Molecular Biology of the Cell 26(1):91–103. https://doi.org/10.1091/mbc.E14-06-1073.

[93] Derivery, E., Sousa, C., Gauthier, J.J., Lombard, B., Loew, D., Gautreau, A., 2009. The arp2/3 activator WASH controls the fission of endosomes through a large multicomponent complex. Developmental Cell 17:712–723. https://doi.org/10.1016/j.devcel.2009.09.010.

[94] Gomez, T.S., Billadeau, D.D., 2009. A FAM21-containing WASH complex regulates retromer-dependent sorting. Developmental Cell 17(5):699–711. https://doi.org/10.1016/j.devcel.2009.08.006.

[95] Van De Sluis, B., Rothuizen, J., Pearson, P.L., Van Oost, B.A., Wijmenga, C., 2002. Identification of a new copper metabolism gene by positional cloning in a purebred dog population. Human Molecular Genetics 11(2):165–173, 11809725.

[96] Tao, T.Y., Liu, F., Klomp, L., Wijmenga, C., Giltin, J.D., 2003. The copper toxicity gene Murr1 directly interacts with the wilson disease protein. Journal of Biological Chemistry 278(43):41593–41597. https://doi.org/10.1074/jbc.C300091200.

[97] Miyayama, T., Hiraoka, D., Kawaiji, F., Nakamura, E., Suzuki, N., Ogra, Y., 2010. Roles of COMM-domain-containing 1 in stability and recruitment of the copper-transporting ATPase in a mouse hepatoma cell line. Biochemical Journal 411:53–61. https://doi.org/10.1042/BJ20100223.

[98] Vonk, W.I.M., Bartuzzi, P., De Bie, P., Kloosters, N., Wichers, C.G.K., Berger, R., et al., 2011. Liver-specific Commd1 knockout mice are susceptible to hepatic copper accumulation. PLoS One 6(12):e29183. https://doi.org/10.1371/journal.pone.0029183.

[99] Jang, H.-D., Lee, S.E., Yang, J., Lee, H.-C., Shin, D., Lee, H., et al., 2019. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. European Heart Journal 41(2):239–252. https://doi.org/10.1093/eurheartj/ehz566.

[100] Seaman, M.N.J., Gauthier, A., Billadeau, D.D., 2013. Retromer-mediated endosomal protein sorting: all WASHeed up! Trends in Cell Biology 23(11):522–528. https://doi.org/10.1016/j.tcb.2013.04.010.

[101] Harbour, M.E., Breusegem, S.Y., Seaman, M.N.J., 2012. Recruitment of the endosomal WASH complex is mediated by the extended ‘tail’ of Fam21 binding to the retromer protein Vps35. Biochemical Journal 441(1):209–220. https://doi.org/10.1042/BJ20111761.

[102] Kim, E., Lee, Y., Lee, H., Su, J., Song, B., Huh, J., et al., 2010. Implication of mouse Vps26b—vps29—vps52 retromer complex in sitofin trafficking. Biochemical and Biophysical Research Communications 403:167–171. https://doi.org/10.1016/j.bbrc.2010.12.121.

[103] Steinberg, F., Gallon, M., Winfield, M., Thomas, E., Bell, A.J., Heesom, K.J., et al., 2013. Global analysis of SNX27-retromer assembly and cargo specificity reveals a function in glucose and metal ion transport. Nature Cell Biology 15(5):461–471. https://doi.org/10.1038/ncb2721-A.

[104] Arighi, C.N., Hartnell, L.M., Aguilar, R.C., Haft, C.R., Bonifacino, J.S., 2004. Identiﬁcation of the copper-transporting ATPase in a mouse hepatoma cell line. Biochemical and Biophysical Research Communications 321:1225–1230. https://doi.org/10.1016/j.bbrc.200312034.

[105] McNally, K.E., Faulkner, R., Steinberg, F., Gallon, M., Ghai, R., Pim, D., et al., 2017. Retromer regulates endosomal cargo transport. Nature Cell Biology 19(10):1214–1225. https://doi.org/10.1038/nccb3610.

[106] Stockinger, W., Sailer, B., Strasser, V., Recheis, B., Fasching, D., Kahr, L., et al., 2002. The PX-domain protein SNX17 interacts with members of the LDL receptor family and modulates endocytosis of the LDL receptor. The EMBO Journal 21(16):4259–4267. https://doi.org/10.1093/emboj/cdf435.
[151] Zavodszky, E., Seaman, M.N.J., Moreau, K., Jimenez-Sanchez, M., Breusegem, S.Y., Harbour, M.E., et al., 2014. Mutation in VPS35 associated with Parkinson’s disease impairs WASH complex association and inhibits autophagy. Nature Communications 5:1—16. https://doi.org/10.1038/ncomms4828.

[152] Conlon, D.M., 2019. Role of sortilin in lipid metabolism. Current Opinion in Lipidology 30(3):198—204. https://doi.org/10.1097/MOL.0000000000000598.

[153] Westerterp, M., Tall, A.R., 2015. Sortilin: many headed Hydra. Circulation Research 116:764—766. https://doi.org/10.1038/sg.75.2.

[154] Chen, C., Li, J., Matye, D.J., Wang, Y., Li, T., 2019. Hepatocyte sortilin 1 knockout and treatment with a sortilin 1 inhibitor reduced plasma cholesterol in Western diet-fed mice. The Journal of Lipid Research 60:539—549. https://doi.org/10.1194/jlr.M089789.

[155] Rabinowich, L., Fishman, S., Hubel, E., Thurm, T., Park, W., Pewzner-Jung, Y., et al., 2015. Sortilin deficiency improves the metabolic phenotype and reduces hepatic steatosis of mice subjected to diet-induced obesity. Journal of Hepatology 62:175—181. https://doi.org/10.1016/j.jhep.2014.08.030.

[156] Li, J., Wang, Y., Matye, D.J., Chavan, H., Krishnamurthy, P., Li, F., et al., 2017. Sortilin 1 modulates hepatic cholesterol lipotoxicity in mice via functional interaction with liver carboxylesterase 1. Journal of Biological Chemistry 292(1):146—160. https://doi.org/10.1074/jbc.M116.762095.

[157] Ren, L., Sun, Y., Lu, H., Ye, D., Han, L., Wang, N., et al., 2018. Prorenin receptor inhibition reprograms hepatic lipid metabolism and protects mice from diet-induced obesity and hepatosteatosis. Circulation Research 122:730—741. https://doi.org/10.1161/CIRCRESAHA.117.312422.

[158] Cullen, P.J., Steinberg, F., 2018. To degrade or not to degrade: mechanisms and significance of endocytic recycling. Nature Reviews Molecular Cell Biology. https://doi.org/10.1038/s41580-018-0053-7.

[159] Krahmer, N., Najafi, B., Schueder, F., Zeigerer, A., Heinz, G., Borner, H., et al., 2018. Organellar proteomics and phospho-proteomics reveal subcellular reorganization in diet-induced hepatic steatosis. Developmental Cell 47:205—221. https://doi.org/10.1016/j.devcel.2018.09.017.